Ming-Yuan Chen
Quick facts
Phase 3 pipeline
- Cisplatin-based induction chemotherapy · Oncology
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells. - Full course of PD-1 monoclonal antibody · Oncology
A monoclonal antibody that binds to PD-1 on immune cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses. - Full course of PD-1blockades · Oncology
PD-1 blockade inhibits the programmed death-1 checkpoint, allowing T cells to recognize and attack cancer cells.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Ming-Yuan Chen
What is Ming-Yuan Chen's pipeline?
Ming-Yuan Chen has 3 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Cisplatin-based induction chemotherapy, Full course of PD-1 monoclonal antibody, Full course of PD-1blockades.
Related
- Sector hub: All tracked pharma companies